Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal)

NICE technology appraisals [TA262] Published date:

NICE is unable to recommend the use in the NHS of adalimumab for the treatment of moderate to severe ulcerative colitis because no evidence submission was received from the manufacturer or sponsor of the technology.

This appraisal relates to people whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

Get involved